紫杉醇靶向化疗治疗小细胞肺癌的效果观察  

Observation on value of paclitaxel targeted chemotherapy for small cell lung cancer

作　　者：孙岩 SUN Yan(Benxi Central Hospital,Benxi 117008,China)

机构地区：[1]本溪市中心医院,117008

出　　处：《中国实用医药》2021年第21期104-106,共3页China Practical Medicine

摘　　要：目的分析紫杉醇靶向化疗治疗小细胞肺癌的临床疗效。方法100例小细胞肺癌患者,依据随机数字表法分为对照组和观察组,每组50例。对照组患者给予常规化疗方案治疗,观察组采取紫杉醇靶向化疗治疗。比较两组生存时间、生存质量、临床疗效及不良反应发生情况。结果观察组生存的时间为(24.45±1.21)个月,长于对照组的(18.01±2.51)个月,差异有统计学意义(P<0.05)。治疗前,两组健康状况调查简表(SF-36)评分比较,差异无统计学意义(P>0.05);治疗后,两组SF-36评分均高于治疗前,且观察组显著高于对照组,差异有统计学意义(P<0.05)。观察组治疗总有效率为74.00%,高于对照组的50.00%,差异有统计学意义(P<0.05)。观察组不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论采用紫杉醇靶向化疗对小细胞肺癌进行治疗,其可有效提高治疗效果,减少不良反应发生,延长生存时间和提高患者的生存质量。Objective To analyze the clinical efficacy of paclitaxel targeted chemotherapy for small cell lung cancer.Methods A total of 100 patients with small cell lung cancer were divided into control group and observation group according to random numerical table,with 50 cases in each group.The control group was treated with routine chemotherapy,and the observation group was treated with paclitaxel targeted chemotherapy.The survival time,quality of life,clinical efficacy,and occurrence of adverse reactions were compared between the two groups.Results The survival time(24.45±1.21)months of the observation group was longer than(18.01±2.51)months of the control group,and the difference was statistically significant(P<0.05).Before treatment,there was no statistically significant difference in 36-item short-form health survey(SF-36)score between the two groups(P>0.05).After treatment,the SF-36 score of the two groups were higher than those before treatment,and the observation group was significantly higher than the control group.All the difference was statistically significant(P<0.05).The total effective rate of the observation group was 74.00%,which was higher than 50.00%of the control group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions of the observation group was lower than that of the control group,and the difference was statistically significant(P<0.05).Conclusion Paclitaxel targeted chemotherapy for patients with small cell lung cancer can effectively improve the therapeutic effect,reduce the occurrence of adverse reactions,prolong the survival time and improve the quality of life of patients.

关 键 词：紫杉醇靶向化疗 小细胞肺癌 治疗价值 

分 类 号：R734.2[医药卫生—肿瘤]